vs
Apellis Pharmaceuticals, Inc.（APLS）与DIGI INTERNATIONAL INC（DGII）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是DIGI INTERNATIONAL INC的1.6倍（$199.9M vs $122.5M），DIGI INTERNATIONAL INC净利率更高（9.6% vs -29.5%，领先39.1%），DIGI INTERNATIONAL INC同比增速更快（17.9% vs -5.9%），DIGI INTERNATIONAL INC自由现金流更多（$35.2M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 6.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Digi International Inc.是总部位于美国明尼苏达州霍普金斯的工业物联网（IIoT）科技企业，成立于1985年。上世纪90年代初，该公司以生产多线路串行数据卡闻名，可支持兼容机运行多线路公告板系统（BBS）。90年代末互联网兴起后，公司逐步转向网络接入设备与工业监测领域布局。
APLS vs DGII — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $122.5M |
| 净利润 | $-59.0M | $11.7M |
| 毛利率 | — | 62.4% |
| 营业利润率 | -25.6% | 13.3% |
| 净利率 | -29.5% | 9.6% |
| 营收同比 | -5.9% | 17.9% |
| 净利润同比 | -62.2% | 16.1% |
| 每股收益（稀释后） | $-0.40 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | $122.5M | ||
| Q3 25 | $458.6M | $114.3M | ||
| Q2 25 | $178.5M | $107.5M | ||
| Q1 25 | $166.8M | $104.5M | ||
| Q4 24 | $212.5M | $103.9M | ||
| Q3 24 | $196.8M | $105.1M | ||
| Q2 24 | $199.7M | $105.2M | ||
| Q1 24 | $172.3M | $107.7M |
| Q4 25 | $-59.0M | $11.7M | ||
| Q3 25 | $215.7M | $10.0M | ||
| Q2 25 | $-42.2M | $10.2M | ||
| Q1 25 | $-92.2M | $10.5M | ||
| Q4 24 | $-36.4M | $10.1M | ||
| Q3 24 | $-57.4M | $11.9M | ||
| Q2 24 | $-37.7M | $9.7M | ||
| Q1 24 | $-66.4M | $4.0M |
| Q4 25 | — | 62.4% | ||
| Q3 25 | — | 63.9% | ||
| Q2 25 | — | 63.5% | ||
| Q1 25 | — | 62.1% | ||
| Q4 24 | — | 62.0% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.2% | ||
| Q1 24 | — | 57.9% |
| Q4 25 | -25.6% | 13.3% | ||
| Q3 25 | 48.7% | 12.5% | ||
| Q2 25 | -18.6% | 13.9% | ||
| Q1 25 | -50.0% | 13.1% | ||
| Q4 24 | -12.3% | 12.9% | ||
| Q3 24 | -24.0% | 14.2% | ||
| Q2 24 | -14.7% | 12.3% | ||
| Q1 24 | -36.0% | 7.6% |
| Q4 25 | -29.5% | 9.6% | ||
| Q3 25 | 47.0% | 8.7% | ||
| Q2 25 | -23.6% | 9.5% | ||
| Q1 25 | -55.3% | 10.0% | ||
| Q4 24 | -17.1% | 9.7% | ||
| Q3 24 | -29.2% | 11.3% | ||
| Q2 24 | -18.9% | 9.2% | ||
| Q1 24 | -38.5% | 3.7% |
| Q4 25 | $-0.40 | $0.31 | ||
| Q3 25 | $1.67 | $0.26 | ||
| Q2 25 | $-0.33 | $0.27 | ||
| Q1 25 | $-0.74 | $0.28 | ||
| Q4 24 | $-0.30 | $0.27 | ||
| Q3 24 | $-0.46 | $0.32 | ||
| Q2 24 | $-0.30 | $0.26 | ||
| Q1 24 | $-0.54 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $30.9M |
| 总债务越低越好 | — | $135.0M |
| 股东权益账面价值 | $370.1M | $649.2M |
| 总资产 | $1.1B | $918.4M |
| 负债/权益比越低杠杆越低 | — | 0.21× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | $30.9M | ||
| Q3 25 | $479.2M | $21.9M | ||
| Q2 25 | $370.0M | $20.1M | ||
| Q1 25 | $358.4M | $26.3M | ||
| Q4 24 | $411.3M | $25.9M | ||
| Q3 24 | $396.9M | $27.5M | ||
| Q2 24 | $360.1M | $28.3M | ||
| Q1 24 | $325.9M | $23.8M |
| Q4 25 | — | $135.0M | ||
| Q3 25 | — | $159.2M | ||
| Q2 25 | — | $40.1M | ||
| Q1 25 | — | $70.0M | ||
| Q4 24 | — | $95.0M | ||
| Q3 24 | — | $123.2M | ||
| Q2 24 | — | $151.6M | ||
| Q1 24 | $93.1M | $171.8M |
| Q4 25 | $370.1M | $649.2M | ||
| Q3 25 | $401.2M | $636.1M | ||
| Q2 25 | $156.3M | $621.5M | ||
| Q1 25 | $164.2M | $605.2M | ||
| Q4 24 | $228.5M | $590.7M | ||
| Q3 24 | $237.1M | $581.0M | ||
| Q2 24 | $264.3M | $563.1M | ||
| Q1 24 | $266.7M | $549.6M |
| Q4 25 | $1.1B | $918.4M | ||
| Q3 25 | $1.1B | $922.6M | ||
| Q2 25 | $821.4M | $770.3M | ||
| Q1 25 | $807.3M | $781.0M | ||
| Q4 24 | $885.1M | $796.1M | ||
| Q3 24 | $901.9M | $815.1M | ||
| Q2 24 | $904.5M | $820.4M | ||
| Q1 24 | $831.9M | $825.3M |
| Q4 25 | — | 0.21× | ||
| Q3 25 | — | 0.25× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 0.12× | ||
| Q4 24 | — | 0.16× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.27× | ||
| Q1 24 | 0.35× | 0.31× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $35.6M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $35.2M |
| 自由现金流率自由现金流/营收 | -7.1% | 28.7% |
| 资本支出强度资本支出/营收 | 0.1% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 3.04× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $111.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | $35.6M | ||
| Q3 25 | $108.5M | $28.0M | ||
| Q2 25 | $4.4M | $24.0M | ||
| Q1 25 | $-53.4M | $26.3M | ||
| Q4 24 | $19.4M | $29.7M | ||
| Q3 24 | $34.1M | $26.4M | ||
| Q2 24 | $-8.3M | $24.9M | ||
| Q1 24 | $-133.0M | $13.1M |
| Q4 25 | $-14.3M | $35.2M | ||
| Q3 25 | $108.3M | $27.5M | ||
| Q2 25 | $4.4M | $22.9M | ||
| Q1 25 | $-53.4M | $25.7M | ||
| Q4 24 | $19.3M | $29.1M | ||
| Q3 24 | — | $25.5M | ||
| Q2 24 | $-8.4M | $24.5M | ||
| Q1 24 | $-133.3M | $12.5M |
| Q4 25 | -7.1% | 28.7% | ||
| Q3 25 | 23.6% | 24.1% | ||
| Q2 25 | 2.5% | 21.3% | ||
| Q1 25 | -32.0% | 24.6% | ||
| Q4 24 | 9.1% | 28.1% | ||
| Q3 24 | — | 24.3% | ||
| Q2 24 | -4.2% | 23.2% | ||
| Q1 24 | -77.3% | 11.6% |
| Q4 25 | 0.1% | 0.4% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 0.5% |
| Q4 25 | — | 3.04× | ||
| Q3 25 | 0.50× | 2.81× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 2.95× | ||
| Q3 24 | — | 2.23× | ||
| Q2 24 | — | 2.57× | ||
| Q1 24 | — | 3.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
DGII
| Io T Productsand Services | $86.4M | 71% |
| Io T Solutions | $36.1M | 29% |
